There will come a time when interconnected diabetes management (IDM) goes mainstream. With all the companies working in this area it’s inventible. Eventually some of these projects will yield a system that not just works but starts to be embraced by patients, physicians and payors. What then? Will we see a dramatic improvement in patient outcomes or more of the same? To be honest we have no idea what will happen.
Looking at this realistically these systems could go mainstream at the same time we have more than one hybrid closed loop insulin delivery system, more than one Tyler . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.